Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7731316 | 0.90 | ESR2 (0.41) | ESR2HTR2CCYP3A4CYP2C9 | |
| SCHEMBL7731315 | 0.90 | ESR2 (0.41) | ESR2HTR2CCYP3A4CYP2C9 | |
| SCHEMBL15744430 | 0.89 | ESR2 (0.36) | ESR2HTR2C | |
| SCHEMBL17548016 | 0.88 | ESR2 (0.40) | ESR2HTR2CCYP3A4CYP2C9 | |
| SCHEMBL7731321 | 0.86 | HTR2C (0.34) | ESR2HTR2CCYP2C9PDE2A | |
| SCHEMBL7731318 | 0.86 | HTR2C (0.34) | ESR2HTR2CCYP2C9PDE2A | |
| SCHEMBL17548014 | 0.86 | ESR2 (0.38) | ESR2HTR2CCYP3A4CYP2C9HRH3 | |
| SCHEMBL13447438 | 0.86 | ESR2 (0.38) | ESR2HTR2CCYP3A4CYP2C9FASN | |
| SCHEMBL15745209 | 0.86 | ESR2 (0.34) | ESR2CYP3A4CYP2C9 | |
| SCHEMBL7733221 | 0.85 | ALDH1A1 (0.43) | ESR2HTR2CCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9605208-B2 | Nematic liquid crystal composition | DIC CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9587175-B2 | Nematic liquid crystal composition | DIC CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160186059-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9321961-B2 | Nematic liquid crystal composition | DIC Corporation (Tokyo) (JP) | 2016-04-26 | — | — | US | disclosed |
| US-9296949-B2 | Nematic liquid crystal composition and liquid crystal display element using the same | DIC CORPORATION (JP) | 2016-03-29 | — | — | US | disclosed |
| US-20150322343-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150284634-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-10-08 | — | — | US | disclosed |
| US-20150218451-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150203757-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150184076-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150159086-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-9039929-B2 | Nematic liquid crystal composition | DIC CORPORATION (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20150060733-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE SAME | DIC CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20140225036-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DIC CORPORATION (JP) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186059-A1 | NEMATIC LIQUID CRYSTAL COMPOSITION | DOCK5, CDKL5, NCS1 | ESR2 4823/4885HTR2C 3900/4885CYP3A4 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.